Popular Posts

Thursday 17 November 2016

Wacker unveils new liquid silicone rubber for medical applications

MUNICH, GERMANY: Wacker Chemie AG unveils a new self-adhesive liquid silicone rubber (LSR) that has a low coefficient of friction, extending its SILPURAN product range. SILPURAN 6760/50 cures to form an elastomer with a low-friction surface, a property which enables self-adhesive LSRs to be used in novel applications.
The silicone adheres readily to selected polyesters such as polybutylene terephthalate (PBT). SILPURAN 6760/50 has been designed for injection moulding, making hard/soft components for medical and pharmaceutical applications suitable for cost-effective large-scale production.
SILPURAN 6760/50 is an addition-curing silicone rubber. It has two components and, once mixed, cures to form a transparent, mechanically robust elastomer with a 50 shore A hardness. After postcuring, the vulcanizates has a coefficient of friction which is between 50 and 70 percent lower than that of standard LSRs of comparable hardness. This makes it possible to use liquid silicone rubber in movable-seal applications. The low coefficient of friction also facilitates the fitting of silicone components into medical devices.
This rubber is specifically designed for the production of parts comprising hard/soft combinations such as those used in the pharmaceutical and medical sectors. They are often made from a hard thermoplastic, which determines the shape, encased in a soft plastic layer. And can be used to cost-effectively injection mould these kinds of parts in large series.
As a self-adhesive grade, it does not need any adhesion promoter. It adheres readily to selected polyesters, such as polybutylene terephthalate (PBT), a thermoplastic often used in injection moulding.
In addition, this rubber meets selected test requirements of ISO 10993 and United States Pharmacopeia (USP) Class VI. Postcured parts are suitable for food-contact applications and can be used under the recommendations of the German Federal Institute for Risk Assessment (BfR) and the US Food and Drug Administration (FDA).

No comments:

Post a Comment